Susanne Diehl

Susanne Diehl serves as Global Program Head Immunology at Novartis, where accountability lies in the early development and commercialization of innovative modalities for severe refractory autoimmune diseases. Previously, Susanne held the role of Global Head Commercial & Pipeline Strategy for Cell & Gene at Novartis Oncology, overseeing cross-functional strategy teams and key multidisciplinary leadership initiatives. Susanne's extensive experience at Novartis includes leadership positions in ophthalmology, where strategic direction was provided for a major launch brand and the German business segment. Earlier, Susanne held various roles at Sandoz, including Franchise Manager for Ophthalmics & Pain and Group Vice President of Corporate Development at Sud-Chemie. Educational qualifications include a PhD in Biochemistry from the Technical University of Munich and additional studies at prestigious institutions such as Harvard Medical School and Columbia Business School.